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ABSTRACT 
A checkerboard broth microdilution method was performed to investigate the in vitro antifungal activities 
of three diazeniumdiolates derivatives (DETA/NO, DPTA/NO, DEA/NO) alone and in combination with 
ketoconazole, amphotricin B or terbinafine against five Candida species, Cryptococcus neoformance and 
four dermatophyte strains. MICs and MLCs were recorded, and synergy was calculated by using 
fractional inhibitory and fractional lethal concentration index. DETA/NO with a half-life of 57h at 25°C 
showed antifungal activity against all tested dermatophyte species (MIC 0.150 to 2.5mg/ml), DPTA/NO 
with a half life of 3h at 37°C showed antifungal activity against five species of Candida and 
Cryptococcus neoformans, and DEA/NO with a half life of 2 min at 37°C and 16 min at 25°C did not 
show antifungal activity against tested strains. Combinations of DPTA-NO with either ketoconazole or 
amphotericin B were either synergistic or indifferent for all tested strain of Candida and Cryptococcus 
neoformance.  DETA/NO was unable to enhance the antifungal activity of terbinafine against 
dermatophyte strains. Even where no synergistic activity was achieved, there was still a decrease in the 
MIC of one or both drugs which were used in combination.  Antagonism was observed between 
terbinafine and DETA-NO against Trichophyton rubrum. Our result suggests that DETA/NO and 
DPTA/NO may be useful for development of new therapeutic strategies for treatment of dermatophyte 
and Candida infections. Clinical studies are warranted to elucidate the potential utility of these 
combination therapies. 
Keywords: NO, Diazeniumdiolates, Antifungal activities, Terbinafine, Amphotericin B, Ketoconazole 
 
INTRODUCTION 
The patient populations at risk for seriousffungal 
infections have increased dramatically in recent 
years. These populations include patients with 
AIDS (1, 2), those receiving cancer chemotherapy 
(3) or organ transplantation (4) and others 
receiving immunosuppressive medications (5). In 
addition, the need for prolonged and repeated 
therapy haslled to the emergence of fluconazole-
resistant isolates of Candida albicans, as well as 
the appearance of other, more resistant species, 
such as Candida glabrata, C. tropicalis, and C. 
krusei (6, 7, 8).Thus, any combination therapy that 
enhance antifungal activity should be actively 
pursued. Combination therapy might be a 
promising approach in such circumstances (9). The 
use of antifungal combinations may increase the 
rates of microbial killing, shorten the durations of 
therapy, reduces the emergence of drug resistance, 
and expand the spectrum of activity (10, 11). Since  
combination therapy carries a much higher cost  
 
and can increase the potential for drug interactions 
and toxicities, it is important to evaluate their 
effects carefully.  
Diazeniumdiolates are capable of releasing NO in 
a biologically usable form. (12) The candidacidal 
activity of diazeniumdiolates, alone and in 
combination with ketoconazole, fluconazole, and 
miconazole has been reported (8). The reported 
data suggest that DETA-NO or compounds with 
similar properties may be useful in development 
of new therapeutic strategies for treatment of 
Candida infections. 
In this study, in vitro activities of three 
diazeniumdiolates, DPTA-NO, DETA-NO and 
DEA-NO alone and in combination with 
ketoconazole, amphotricin B and terbinafine, 
against C.albicans, C.glabrata, C.tropicalis, 
C.parapsilosis and four dermatophyte species 
including Trichophyton mentagrophytes, 
T.rubrum, Microsporum canis, M.gypseum and 
Cryptococcus neoformans were investigated.  
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MATERIALS AND METHODS 
 
Fungal strains 
Candida strains included PTCC (Persian Type 
Culture Collection)5027 Candida albicans and 
dermatophyte strains included Microsporum 
gypseum, PTCC 5070 Microsporum canis PTCC 
5060 and Trichophyton rubrum PTCC 5143 which 
were obtained from Iranian Scientific and 
Industrial Institute. Candida parapsilosis, C. 
tropicalis, two type of C. glabrata (resistance and 
susceptible to ketoconazole), Cryptococcus 
neoformance and Trichophyton mentagrophyte 
were isolated from patients at Mycology 
department of Iran Medical Science University. 
All Candida strains were evaluated on SC agar 
(Sabouraud's dextrose agar + chloramphenicol) for 
presumptive identification, and identity was 
verified by API kit (api 20 C AUX, boimerieux 
sa). Strains were stored at –70°C in 20% glycerol. 
Prior to initiation of the study, the strains were 
subcultured on antimicrobial agent-free medium to 
ensure viability and purity. (13) 
After presumptive identification, Cryptococcus 
neoformance was subcultured on BHI agar (Brain 
Heart Infusion Agar). Dermatophyte strains’ 
identity were confirmed by slide culture and 
urease test (14). All strains were maintained in 
20% glycerul-10% lactose in liquid nitrogen. 
 
Antifungal agents  
Ketoconazole and amphotricin B were obtained 
from Sigma chemical Co. Terbinafine was a gift 
from Tehran Chemistry Co. NO releasing 
compounds including DEA/NO; sodium (Z)-1-(N, 
N-diethlamineo), DETA/NO; (Z)-1-[N-(2-amino-
ethyle)– N- (2-aminoethyle) amino] diazen-1-ium-
1,2-Diolate and DPTA/NO (3,3'-(Hydroxynitroso-
hydrazino)bis-1-propanamine) were obtained from 
Alexis Chemical Co. 
Stock solutions of ketoconazole, amphotricin B 
and terbinafine were prepared in dimethyl 
sulfoxide (Sigma). Stock solutions of diazenium-
diolates were prepared in sterile RPMI-1640. 
Further dilutions of all drugs were prepared in the 
test medium. 
 
Broth dilution assay 
Drug activity was assessed by a checkerboard 
method derived from the standardized procedure 
established by the National Committee for Clinical 
Laboratory Standards (NCCLS) for broth 
microdilution antifungal susceptibility testing. 
Briefly, testing was performed in RPMI 1640 
medium (Sigma) buffered to pH 7.0 with 0.165 M 
morpholinepropanesulfonic acid (MOPS; Gibco 
Laboratories) buffer. One hundreds microliters of 
a two fold concentration of each drug (or 50µl of a 
four fold concentration for the studying of two 
drugs in combination) were dispensed in the wells 
of 96-well microtiter plates (Falcon 3072; Becton 
Dickinson). The range of concentrations of the 
antifungal agents after  addition of inocula were 
0.125-64 µg/ml for ketoconazole, 0.007-1 µg/ml 
for terbinafine, 0.001-64 µg/ml for amphotricin B 
and 0.01-5 mg/ml for NO-generation compounds. 
Fungi inocula (100µl), were prepared 
spectrophotometrically and  diluted further in 
order to obtain concentrations ranging from 104 
CFU/ml of 18h old Candida cells or 48h old 
Cryptococcus neoformans cells and 105 CFU/ml 
containing 4-7 days old dermatophytes (2x 
inoculum), when added to each well of the 
microtitre plates to a final volume of 200µl.  Plates 
were incubated for 24 -48 h at 37ºC for yeast 
species and 4-7 days at 28ºC for dermatophytes 
(13, 15). The minimum inhibitory concentration 
(MIC) of agents was determined visually, as the 
lowest concentration at which no growth was 
observed. The minimum lethal concentrations 
(MLC) of each drug, alone or in combination, 
were determined by plating 100µl sample from 
wells showing no observable growth onto 
sabouraud dextrose agar. MLCs were defined as 
the lowest concentration of the agent that at which 
no colonies were observed after 24h for Candida 
spp. and 4 days for dermatophytes. The reported 
final data are theaaverage of three independent 
experiments. 
In synergy studies, the fractional inhibitory 
concentrations (FIC) of each drug used in 
combination were calculated and added to obtain 
the FIC indices. 
FIC index is equal to: (MIC of drug A in 
combination/MIC of drug A alone)+(MIC of drug 
B in combination/MIC of drug B alone). 
Drugs interactions were judged on the basis of the 
following criteria: synergistic effect (≥0.5) 
indifferent effect (0.5 - ≤4) and antagonistic effect 
(>4) (16). The fractional lethal concentration 
(FLC) index was calculated from a formula 
similar to that for the FIC index but by 
substitution of MLC for MIC. 
 
RESULTS 
 
Antifungal effects of DPTA/NO 
The results of susceptibility to DPTA-NO alone 
and in combination with ketoconazole and 
amphotricin B by the broth dilution assay are 
presented in Table 1. When DPTA/NO was used 
alone, the MICs ranged from 156 to 2500 µg/ml 
and when DPTA-NO was combined with 
ketoconazole, there were significant reductions in 
its MIC values ranging from 39 to 625 µg/ml. The 
most and the least sensitive Candida strains 
against DPTA-NO alone were C. parapsilosis and 
C. glabrata(R). MICs of ketoconazole alone 
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Table 1.  Inhibitory effects of DPTA/NO on proliferation of selected fungal species in the presence or absence of 
antifungal drugs. 
MIC (µg/mL)  MIC (µg/mL)    
Strain Ketoconazole Ketoconazole  
with DPTA-NO 
FIC DPTA-NO DPTA-NO 
with azole 
FIC FIC 
Index 
C. albicans 1 0.5 0.5 625 312 0.5 0.99 
C. parapsilosis  0.5 0.125 0.25 156 78 0.5 0.75 
C. glaborata NR 4 2 0.5 1250 625 0.5 1 
C. glaborata R 32 4 0.125 2500 312 0.124 0.24 
C. tropicalis 16 0.5 0.031 1250 39 0.03 0.06 
MICs were determined visually as the concentration that gave 100% inhibition. The MIC values represent the average 
of 3 independent experiments. 
NR: Susceptible to ketoconazole, R:Resistance to ketoconazole 
 
 
 
Table 2. Inhibitory effects of DPTA/NO on proliferation of selected fungal species in the presence or absence of 
amphotricin B. 
 Amphotricin  B Amphotricin B with  DPTA-NO DPTA-NO 
DPTA-NO with 
 Amphotricin B 
Cryptococcus neoformans 1 0.003 0.003 19 0.1 0.005 0.008 
MICs were determined visually as the concentration that gave 100% inhibition. The MIC values represent the average 
of 3 independent experiments. 
 
 
 
Table 3. Fungicidal effects of DPTA/NO on selected fungal species in the presence or absence of antifungal drugs. 
MLC was determined as the lowest concentration of the agent at which no colonies were observed after 24 h for yeasts and 4 days 
for dermatophytes. The MLC values represent the average of 3 independent experiments. 
NR: Susceptible to ketoconazole,  R:Resistance to ketoconazole 
 
 
 
Table 4. Fungicidal effects of DPTA/NO on selected fungal species in the presence or absence of amphotricin B. 
MLC was determined as the lowest concentration of the agent at which no colonies were seen after 24 h for yeasts and 4 days for 
dermatophytes. The MLC values represent the average of 3 independent experiments 
 
 
Table 5. Inhibitory effects of DETA/NO on proliferation of selected fungal species in the presence or absence of 
antifungal drugs. 
MIC (µg/mL)  MIC (µg/mL)  
Strain 
Terbinafine 
Terbinafine 
with 
DETA-NO 
FIC DETA-NO 
DETA-NO 
with 
Terbinafine 
FIC FIC Index 
Microsporum gypseum 0.03 0.03 1 1250 312 0.24 1.24 
Microsporum canis 0.003 0.007 2.33 156 19 0.12 2.45 
Trichophyton rubrum 0.01 0.06 6 2500 625 0.25 6.25 
Trichophyton 
mentagrophytes 0.03 0.03 1 625 312 0.49 1.49 
MICs were determined visually as the concentration that gave 100% inhibition. The MIC values represent the average of 3 
independent experiments. 
MLC (µg/mL)  MLC (µg/mL)    
Strain Ketoconazole Ketoconazole  with DPTA-NO FLC DPTA-NO 
DPTA-NO 
with azole FIC 
FLC 
Index 
C. .albicans 4 2 0.5 2500 1250 0.5 1 
C. parapsilosis  4 2 0.5 5000 1250 0.25 0.75 
C. glaborata NR 32 16 0.5 5000 1250 0.25 0.75 
C. glaborata R 64 32 0.5 5000 2500 0.5 1 
C. tropicalis 32 16 0.5 2500 1250 0.5 1 
 Amphotricin B Amphotricin B with  DPTA-NO DPTA-NO 
DPTA-NO with  
Amphotricin B 
Cryptococcus neoformans 2 0.001 0.0005 39 0.5 0.01 0.0125 
Interaction between diazenumdiolates and some antifungals
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ranged from 0.5 to 30 µg/ml, while in combination 
with DPTA-NO ranged from 0.125 to 4 µg/ml. 
C. parapsilosis was the most susceptible strain 
against ketoconazole alone and in combination. 
The FIC index showed synergy between DPTA-
NO and ketoconazole against C. glabrata(R) and 
C. tropicalis and indifferent interaction against 
other tested Candida species The MLCs values of 
DPTA-N0 alone, ranged from 2.5 to 5 mg/ml and 
in combination with ketoconazole, MLC values of 
both agents were reduced significantly. The FLC 
indices confirmed the synergistic effect inferred 
from the FIC values (Table2). 
DPTA/NO showed the greatest antifungal activity 
against Cryptococcus neoformans. When 
DPTA/NO was combined with amphotricin B, 
there was an almost 200 fads decrease in the MIC 
value for DPTA/NO against Cryptococcus 
neoformans .  In the presence of DPTA/NO a 
similar decrease in the MIC of amphotricin B 
against Cryptococcus neoformans (almost 300 
fold) was observed.  The MLC value of DPTA-
NO in combination with amphotricin B was at 
least 80-fold lower than that for DPTA-NO alone.  
Higher decrease (2000-fold) was shown for MLC 
of ketoconazole in combination with DPTA-NO 
against Cryptococcus neoformans. Data are 
presented in table 2.  
 
Antifungal effects of DETA/NO 
The MIC values for the anti fungal effects of 
DETA/NO, alone and in combination against 
selected strains of Tricophytone and Microsporum 
are presented in Table (3). Presence of DETA/NO 
didn't produce a great change in the MIC value of 
terbinafine against these organisms and the 
interaction was indifferent. However, the presence 
of terbinafine reduced the MIC value of 
DETA/NO against M. canis and M. gypseum 
significantly. The results also showed that there 
was an antagonism between DETA-NO and 
terbinafin against T.rubrum  
 
Antifungal activity of DEA/NO 
DEA/NO did not show antifungal activity against 
any of the tested fungi including: Candida spp., 
Cryptococcus neoformans and dermatophyte 
strains. 
 
DISCUSION 
The emergence of antifungal resistant strain of 
various fungi such as Candida, dermatophyte and 
Cryptococcus neoformans has prompted research 
for development of new strategies for treatment of 
fungal infections (7, 17, 18).  The identification of 
NO as an antifungal agent (19), which is active 
against a number of pathogenic fungi, has offered 
new opportunities for development of such 
strategies (20, 21, 22, 23, 24), while at the same 
time has presented new challenges due to the wide 
physiological effects of NO which increases 
likelihood ofuunacceptable adverse effects (6). In 
addition, instability of NO under physiological 
conditions makes delivery of the agent to the site 
of infections difficult (25) and the mainpproblem 
with the use of No has been reported to be its short 
half life and its limited solubility (26). 
Diazeniumdiolates with the general structure of  
XN (O) N=O (where X is a nucleophile residue) 
are capable of releasing NO in an aqueous 
environment (27, 28, 29).  These compounds do 
not require activation through a redox reaction or 
electron transfer as do glyceryl trinitrate and 
sodium nitroprusside (30). Diazeniumdiolate are 
stable and capable of delivering NO in a 
biologically useable form at a predictable rate.  
Three of such compounds are DPTA/NO, 
DETA/NO and DEA/NO. Work by other 
researchers showed in vitro synergy or additive 
effect between DETA-NO and azole against some 
candida species (12) has been reported. In the 
presentsstudy aacheckerboard broth microdilution 
method was performed to investigate the in vitro 
antifungal activities of DPTA-NO, DETA-NO and 
DEA-NO alone and in combination with three 
currently used drugs: ketoconazole, amphotericin 
B and terbinafine against five Candida species, 
Cryptococcus neoformance and four dermato-
phytes strains. The results obtained in this work, 
suggest that the rate of NO release is an important 
factor in the antifungal effects of these 
compounds, as DEA/NO with ahhalfllife about 2 
minutes didn’t show any antifungal activity.  
The data obtained in this work demonstrated an 
effective interaction between DPTA-NO and 
ketoconazole against five Candida species 
especially clinical isolates of C. glabrata. The FIC 
index calculated for the combined effects of 
ketoconazole and DPTA-NO, on various Candida 
species suggests that the detoconazole and DPTA-
No have synergistic effect against C.tropicalis and 
C.glabarata R. Candida glabrata R has recently 
emerged as a significant pathogen involved in 
voth superficial and deep-seated infections 
(16,19). The prominence of C.glabrata R as a 
pathogen is of particular clinical concern because 
it is innately less susceptible to fluconazole and 
amphotericin B than most other spesies of 
Candida (19), and infections due to C.glabrata are 
characterized by a high mortality rate. 
Combination of, DPTA-NO and ketokonazole had 
indifferent effect, against C.albicans, C.para-
psilosis and C.galaborata NR. Also, the different 
effect values of FIC index obtained for different 
species of the Candida genus, suggest that the 
effects of combination of two drugs, depends not 
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only on the drugs themselves, but also on the 
microorganism that the combination acts on.  
Results of this study also demonstrated that there 
is a notable synergistic interactions between 
DPTA-NO and amphotericin B against Crypto-
coccus neoformans. The encapsulated fungus 
Cryptococcus neoformans is a significant cause of 
morbidity and mortality in patients with impaired 
cell-mediated immunity, especially those with 
AIDS (It is an opportunistic fungal pathogen that 
causes life-threatening meningoencephalitis in 5 to 
10% of AIDS patients) (32, 33). 
All three fungicidal compounds tested, change 
fungal cell membrane permeability via different 
mechanisms. Ketoconazole, like other azoles, 
affects ergosterol biosynthesis (34,35), 
amphotericin B binds to ergosterol (36), and 
terbinafine binds squalene epoxidases leading to 
ergosterol deficiency (37).  However, the effects 
of NO donors, when combined with these 
fungicidal agents were not similar. DPTA-NO 
exhibited synergistic effect with ketoconazole and 
amphotericin B, while DETA-NO showed little 
effect when combined with terbinafine. The 
effects of DPTA-NO when used in combination 
with ketoconazole and amphotericin B may be due 
to enhanced entry of the NO donor into the cell 
due to membrane damage which is caused by the 
 
fungicidal agents.  However, enhanced entry of the 
NO donor into the cell is not the only factor 
involved. Since when terbinafine and DETA-NO 
were used in combination, there were no 
enhancement of the fungicidal effects of the 
former.  This could be due to the long half-life of 
DETA-NO (57h) which would mean a much 
slower release of NO compared to DPTA-NO 
(half life = 2.5h). Therefore, although in the 
presence of terbinafine, DETA-NO enters the 
fungal cell more easily (as suggested by the 
decrease in the MIC of DETA-NO in the presence 
of terbinafine), the rate of generation of NO by 
DETA-NO is not fast enough to generate effective 
fungicidal levels of NO. 
 
CONCLUSION 
DPTA-NO appears to be the most suitable NO 
donor which was tested in this work. Our data 
suggest that DPTA-NO may be effective when it 
is used in combination with ketoconazole and 
amphotericin B for the treatment of Candida 
especially C. glabrata resistant to ketoconazole 
and Cryptococcus neoformans infections. 
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